ArticleChronic obstructive pulmonary diseases (Miami, Fla.)2021

InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions.

Arnaud Bourdin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.